About US
Contact us
-
S&P doesn't buy AstraZeneca CEO's revamp planStandard & Poor's is not impressed with AstraZeneca's jump-start plan. The ratings agency cut the U.K.-based drugmaker's credit ratings, citing CEOPascal Soriot's strategy update last month,Reute2013/4/9
-
Roche inks $392M Huntington's disease pact with IsisRoche ($RHHBY) has stepped up with a $392 million deal designed to marry its work on new technology for delivering brain treatments with Isis' ($ISIS) antisense programs for Huntington's disease. In2013/4/9
-
Judge gives FDA 30 days to make Teva's Plan B available to adolescents OTCA federal judge has told the FDA to do exactly what the agency tried to do two years ago: make the "morning after"birth controlpill freely available to girls of all ages without a prescription. U.S2013/4/8
-
China obtains ISO/TC150/SC7 voting rightsOn March 26, 2013, the secretariat of Tissue Engineered Medical Products Subcommittee of National Technical Committee on Implants for Surgery and Orthopedic Devices of Standardization Administration2013/4/8
-
India's top court rebuffs Merck, lets generic Januvia roll outIndia's Supreme Court is keeping the pressure on Western drugmakers. Just days after invalidating a patent for Novartis' ($NVS) cancer drugGlivec, it has said a generic drugmaker there is free, for2013/4/7
-
Roche's Tamiflu, GSK's Relenza work against new bird flu strainChina will lean on the Roche ($RHHBY) drugTamifluto treat those infected with a new strain of bird flu that has so far sickened 16, killing 6. Authorities in Shanghai emphasized that the H7N9 virus i2013/4/7
-
Merz swoops into Obagi deal with $385M bid, topping ValeantThese days, dermatology is the belle of the ball. Drugmakers have been wooing small players in the skin-treatment field, and just last month, Valeant Pharmaceuticals ($VRX) announced that it had agre2013/4/3
-
Lilly bets on new insulin products with $180M plant additionEli Lilly ($LLY) has made a huge bet on insulin to help it maneuver past patent losses for drugs like antidepressant Cymbalta which falls off this year. It has four new products in development, inclu2013/4/3
-
J&J faces big spending, big rivals for new diabetes drug InvokanaJohnson & Johnson's new diabetes drug Invokana, previously known as canagliflozin, is the first FDA-approved treatment in a new class. That's something of a double-edged sword. It offers the prom2013/4/2
-
As Novartis loses Glivec bid, India's war on pharma patents threatens to spreadNovartis ($NVS) lost its last bid for an Indian patent on its cancer drug Glivec. As the nation's Supreme Court prepared to rule Big Pharma braced itself for impact. India has blazed a patent-slashin2013/4/2